Ad hoc announcement pursuant to Art. 53 LR Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients
Newron announces 2020 financial results and provides outlook for 2021
DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): Annual Report
16.03.2021 / 07:00
Newron announces 2020 financial results
and provides outlook for 2021
Milan, Italy, March 16, 2021 - Newron Pharmaceuticals S.p.A. ( Newron ) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the year ended December 31, 2020, and provided an outlook for 2021.
Highlights 2020:
Evenamide (Schizophrenia)
All evenamide pre-clinical studies requested by the US Food and Drug Administration (FDA) have been completed with no toxicity concerns identified